US mRNA specialist Moderna today announced that the European Commission (EC) has granted marketing authorization for mNEXSPIKE (mRNA-1283), a new COVID vaccine, for active immunization to prevent ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Moderna’s updated COVID-19 mRNA vaccine, Spikevax targeting the SARS-CoV-2 LP.8.1 variant, for adults and children aged ...

Moderna has early in-human data showing its next-generation COVID-19 vaccine, mNEXSPIKE, has the potential to offer strong immune protection against the latest rapidly spreading SARS-CoV-2 virus.

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

Walensky is a professor at Harvard Medical School and served as the 19th director of the Centers for Disease Control and Prevention. Once clinical trials showed that Covid-19 vaccines were safe and ...

Amid the declining clinical severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and diminishing public uptake of annual coronavirus disease 2019 (Covid-19) vaccines, ...

A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived dramatically longer than those who didn’t. Researchers from the ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

A new vaccine designed to provide broad protection against COVID-19 and related coronaviruses has begun human trials. The ...